Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Drops By 41.9%

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 3,600 shares, a decline of 41.9% from the October 15th total of 6,200 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 12,000 shares, the days-to-cover ratio is currently 0.3 days.

Alterity Therapeutics Trading Down 5.6 %

Shares of NASDAQ ATHE traded down $0.07 during trading hours on Friday, hitting $1.11. The stock had a trading volume of 13,112 shares, compared to its average volume of 44,340. Alterity Therapeutics has a 52 week low of $1.01 and a 52 week high of $5.41. The firm’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $1.58.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.